Novel Use of Biomarkers in Predicting Outcomes in Patients With Acute Coronary Syndrome

Abstract

Despite the significant improvement in treatment options, cardiovascular disease (CVD), continues to be one of the leading causes of morbidity and mortality in the United States for almost a century. The increasing availability of more potent antithrombotic medication carries a significant therapeutic benefit in patients with acute coronary syndrome (ACS). However, this increased benefit comes with potentially significant side effects. Theoretically, rivaroxaban would have the greatest benefit in patients who are at a very high risk of another cardiovascular event but are at a very low risk of a bleeding event. While certain demographic characteristics may help risk stratify patients, this process can be further refined by incorporating biomarkers. This thesis will focus on both ischemic and bleeding outcomes, both highly relevant in a clinical setting. Additionally, we will demonstrate the applicability of these biomarkers in a new and growing population of patients with ACS, those who are also on rivaroxaban. Ultimately, our aim is to highlight the potential of biomarkers in aiding a physician decide on the appropriate treatment.